![syn stocktwits syn stocktwits](https://www.marketbeat.com/logos/ra-pharmaceuticals-inc-logo.jpg)
Data from a recent canine study completed during the second half of 2017 demonstrated that, when co-administered with oral amoxicillin, SYN-007 did not interfere with amoxicillin absorption and demonstrated protection of the gut microbiome. SYN-007 extends gut microbiome protection from antibiotic-mediated dysbiosis by continuing protection after patients have been transferred from an intravenous (IV) beta-lactam antibiotic to an oral beta-lactam antibiotic. SYN-007 is a specially formulated version of SYN-004 (ribaxamase) designed to degrade orally administered beta-lactam antibiotics to protect the gut microbiome from antibiotic-mediated dysbiosis. We have successfully formulated SYN-006 for oral delivery and evaluated it in a porcine efficacy model in conjunction with IV ertapenem. difficile infection, and enable GI overgrowth with multidrug resistant organisms.
![syn stocktwits syn stocktwits](https://i.ytimg.com/vi/FUwSMay2Cxo/maxresdefault.jpg)
Carbapenems are broad-spectrum beta-lactam antibiotics that have been shown to significantly damage the gut microbiome, incur a high risk for C. SYN-006 is a carbapenemase designed to degrade intravenous (IV) carbapenem antibiotics within the gastrointestinal (GI) tract to maintain the natural balance of the gut microbiome for the prevention of CDI, overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR).